Jersey government in push to make finance sector more competitive
Speaking at an event for industry leaders last week, Gorst said: "The major part of our economy is financial and professional service, and if that industry remains strong and grows, it means we will have tax take."It means we will have a strong economic future, if we let that industry decline and if we don't get on the front foot, and we aren't competing with Luxemburg, Singapore and Hong Kong, then our industry will decline."
Mr Christensen, who is also director of the Balanced Economy project, said: "We are reaching the stage at which democracy itself is at risk of collapse and we are moving into the territory of authoritarian regimes."So any measure to compete against other tax havens by deregulating and by lowering tax will only and inevitably benefit the very powerful and the very rich."
Jill Britton, director-general of the Jersey Financial Services Commission, acknowledged Jersey was competing in a complex global situation."There is an international set of standards for many international organisations," she said."That's happening is across the different regions is there is a wholesale review of those standards, which means the standards internationally as we have known them are not being applied in the same way."We are having to respond very quickly to that level of complexity."
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Guardian
26 minutes ago
- The Guardian
Donald Trump's war on statistics is an authoritarian attack on democracy and countries like Australia should call it out
Whether it be the judicial system, universities, or health organisations, Donald Trump cannot abide by anything that does not confirm his world view. So it was not a shock when late last week he came for statistics – or, more pointedly, the person in charge of the economic statistics. On Friday, the US's Bureau of Labor Studies released the July US employment figures. They were not good. Just 73,000 non-farm jobs were added and annual employment growth was the worst it has been since the GFC years (excluding the pandemic): If the graph does not display click here In response, Trump did what any autocrat would do when told bad news: he shot the messenger – at least only figuratively. Trump argued that Erika McEntarfer, the commissioner of labor statistics, had faked bad figures purely to hurt him. And so he fired her. But this should not be dismissed as 'oh that's just Trump', nor should we just sigh and say we have been in a fact-free era for nearly a decade. Reality might be hanging on to the political debate for dear life, but this move threatens to fling it off the cliff. The BLS data is vital for understanding not just what is going on in the USA but to guide other nations – like here in Australia. For example, Australia is doing very well compared with the US. Unlike the US, our employment rate is higher now than it was before the pandemic: If the graph does not display click here These comparisons can influence future policies. For example, we did very well during the GFC; the US did not. We also did much better during the pandemic than the US. They also give insight into the future. The US is still the world's biggest economy and – as we have seen with inflation – what happens there, often happens here, in Australia: If the graph does not display click here If Trump doesn't like weak employment growth numbers, you think he'll be happy with inflation data that shows his tariffs are causing higher prices? And this is not just some academic exercise. US welfare payments are indexed to inflation, so the official data vitally affects the livelihood of many people. Trump thinks when he closes his eyes the rest of the world disappears. But not measuring inflation or unemployment or global temperatures doesn't disappear the problems. And loss of trust in official data will affect business investment decisions, borrowing costs and – as with all attacks on institutions – faith in democracy. For example, in Australia, the Australian Bureau of Statistics has revealed that in the past year the cost of living for all households except 'self-funded' retirees rose faster than did inflation: If the graph does not display click here This is not the greatest news for the Australian government – no politician likes data that says things might be worse than what they previously argued. Cost of living, unlike inflation, includes mortgage repayments. Despite falling interest rates, repaying a mortgage is still around 4.4% higher than it was a year ago, and since March 2022 mortgage repayments have accounted for nearly half of the increase in cost of living: If the graph does not display click here Does it help the Australian government for the ABS to reveal this? Not really. It could blame our Reserve Bank, but generally governments are blamed for high interest rates. It certainly doesn't help the government for the ABS to release figures that some journalist like me can use to show that the value of wages are 8.6% lower than they were in March 2021 when you use cost of living rather than CPI: If the graph does not display click here That type of information makes life hard for the government – but so it should! In a democracy you have to face your critics, argue your case and convince voters you have the best plans and way forward. Political parties are already working hard to make you question reality. But at least till now, even in the US, where Trump would like there to be a new kind of maths where prices can fall by more than 100% (1,000%, 1,100, 1,200, 1,300!!), reality has been counted and presented. The end of impartial economic data would not just be another case of Trump 'flooding the zone'. It would be a fundamental attack on democracy, designed to ensure those who are suffering from his polices are not able to demonstrate that things are worse – either for them or for the nation. They are the actions usually associated with authoritarian regimes, and we should not shy away from making that clear. Greg Jericho is a Guardian columnist and policy director at the Centre for Future Work
The Guardian
41 minutes ago
- The Guardian
Sales of Novo Nordisk's diabetes drugs including Ozempic slow sharply
Sales of Novo Nordisk's injectable diabetes drugs including Ozempic have slowed sharply amid fierce competition and the threat of US tariffs, prompting it to cut costs and sharpen its commercial focus. The Danish drugmaker, whose booming sales of GLP-1 diabetes and obesity drugs in recent years had turned it into Europe's most valuable company, has lost nearly $100bn (£75bn) in market value since cutting its full-year sales forecast last week, when its share price slid 30% in its worst week in more than two decades. It fell a further 3% on Wednesday. On Wednesday, Novo Nordisk said sales of medications such as Ozempic – which mimic the GLP-1 gut hormone that regulates blood sugar levels and appetite – grew by 8% in the first half of the year, down from 21% last year. Sales of obesity drugs including Wegovy increased by 56%, taking total sales 16% higher to 155bn Danish kroner (£18bn). Profit before tax climbed by 24% to 70.8bn kroner. The company has lost market share to its US rival Eli Lilly's Mounjaro, which studies have shown to be more effective, as well as cheaper versions made by generic drugmakers. It has also been hit by 'compounding' in the US, where pharmacies make up medications from ingredients, even though the US regulator declared an end to the practice recently. Novo Nordisk's outgoing chief executive, Lars Fruergaard Jørgensen, said that the copycat market had 'equal size to our business' and that compounded versions of Wegovy were sold at a 'much lower price point'. Its finance chief, Karsten Munk Knudsen, said the company was pursuing various strategies, including lawsuits against compounding pharmacies and expanding its US direct-to-consumer platform, NovoCare, launched in March. The company might also pursue 'cash sales' directly to patients elsewhere. Jørgensen said Novo Nordisk was taking measures to 'sharpen our commercial execution further, and ensure efficiencies in our cost base while continuing to invest in future growth'. He said it would probably not be able to avoid layoffs, but that no decision had been made. He said it would be up to Maziar Mike Doustdar, who takes over as CEO on Thursday, to make such a decision. The company is now expecting sales growth of between 8% and 14% at constant exchange rates in 2025, down sharply from its previous estimate of 13% to 21%. Novo Nordisk also disclosed that it had ditched several weight-loss drugs in development, including one that has just completed an intermediate (phase II) clinical study, 'due to portfolio considerations'. The company faces a class action lawsuit in the US from investors, who claim that it misled them with optimistic growth forecasts in the lucrative weight loss market. The UBS analyst Matthew Weston said: 'We expect GLP-1 compounders to remain in the US, which limits cash-pay uptake and leaves an uncertain outlook for US Wegovy. Sign up to Business Today Get set for the working day – we'll point you to all the business news and analysis you need every morning after newsletter promotion 'President Trump's proposal to reimburse GLP-1 obesity in Medicare could add significant volume uplift, but most-favoured-nation demands to offer US cash sales at European prices could significantly reduce value.' Derren Nathan, the head of equity research at Hargreaves Lansdown, said: 'Tariffs and drug pricing policy are another threat Mike Doustdar will need to tackle head-on if one of Denmark's greatest success stories is to regain its crown as Europe's most valuable company. 'The 15% blanket rate on EU imports is not necessarily the end of the story as Donald Trump dangles the prospect of levies of up to 250% on pharmaceutical imports under a separate section 232 investigation.'
The Sun
an hour ago
- The Sun
Future of chain Claire's on UK high streets uncertain after US parent firm files for bankruptcy
FASHION accessories chain Claire's is facing an uncertain future on UK high streets, after its US parent firm filed for bankruptcy. It is the second time the ear-piercing favourite has declared itself bust, after previously filing for bankruptcy in 2018. 1 Its finances are now under pressure from weak consumer demand and supply chain uncertainty. The filings showed that the parent business reported liabilities of up to $10billion (£7billion) and owed between 25,000 and 50,000 creditors. Claire's operates 2,750 stores worldwide, including 280 in the UK. While British stores remain unaffected for now, the UK arm has lost £25million over the past three years and is at risk of collapsing into administration later this month. It has been working with advisers to explore a sale or restructuring. However, potential buyers, such as Hilco Capital, are understood to have walked away. Retail experts say Claire's is struggling to stay relevant. Julie Palmer, from Begbies Traynor, said: 'Claire's low-price offering is clearly not strong enough to win over its core customers — teens and young adults — as they now have access to a vast array of affordable and convenient products online through platforms like Amazon and Temu.' Claire's boss Chris Cramer said: 'We remain in active discussions with potential strategic and financial partners and are committed to completing our review of strategic alternatives.' Nostalgic 90's retailer files for bankruptcy after chain misses rent payments for June and July 'CORE BLIMEY! MINING giant Glenciore has decided to stick with its London stock listing, scrapping plans to shift to New York, in a win for the City. It has been listed on the FTSE since 2011, when it was valued at £37billion — at the time the exchange's largest float. However, the Swiss-based firm has announced plans to slash £753million in costs by 2026, including job cuts across its 150,000-strong workforce. METRO BANK ON THE UP METRO BANK has bounced back, posting a £43.1million pre-tax profit for the first half of 2025 — up from a £33.5million loss reported in the same period last year. The lender doubled new corporate and small business loans to £1billion, and cut 8 per cent from its costs by axing a third of its workforce and reducing branch hours. Boss Daniel Frumkin said: 'Our strong performance reflects the decisive actions we have taken.' Elsewhere, Sabadell shareholders have approved the £2.65billion sale of TSB to Santander.
